-transparent.png){kind=logo}
Bufexamac is an anti-inflammatory agent used as topical treatment of various pruritic diseases. Since it was put on the market, this product has been blamed for the occurrence of contact dermatitis (eczema, urticaria) and, rarely, severe toxicodermia. We report a case of severe contact dermatitis developed after application of bufexamac (Parfenac) cream. Patch-tests performed two months after the acute phase were positive (+ + +) for both Parfenac cream and bufexamac.
Related Publications
E Collet, and
M Lacroix, and
C Boulitrop Morvan, and
S Dalac, and
J Sallin, and
D Lambert
December 2009,
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne,
E Collet, and
M Lacroix, and
C Boulitrop Morvan, and
S Dalac, and
J Sallin, and
D Lambert
June 1996,
American journal of contact dermatitis : official journal of the American Contact Dermatitis Society,
E Collet, and
M Lacroix, and
C Boulitrop Morvan, and
S Dalac, and
J Sallin, and
D Lambert
January 1996,
Annales de dermatologie et de venereologie,
E Collet, and
M Lacroix, and
C Boulitrop Morvan, and
S Dalac, and
J Sallin, and
D Lambert
September 2011,
Contact dermatitis,
E Collet, and
M Lacroix, and
C Boulitrop Morvan, and
S Dalac, and
J Sallin, and
D Lambert
January 1996,
Journal of the American Academy of Dermatology,
E Collet, and
M Lacroix, and
C Boulitrop Morvan, and
S Dalac, and
J Sallin, and
D Lambert
February 2018,
Contact dermatitis,
E Collet, and
M Lacroix, and
C Boulitrop Morvan, and
S Dalac, and
J Sallin, and
D Lambert
June 2020,
Contact dermatitis,
E Collet, and
M Lacroix, and
C Boulitrop Morvan, and
S Dalac, and
J Sallin, and
D Lambert
August 1999,
The British journal of dermatology,
E Collet, and
M Lacroix, and
C Boulitrop Morvan, and
S Dalac, and
J Sallin, and
D Lambert
July 2013,
Contact dermatitis,
E Collet, and
M Lacroix, and
C Boulitrop Morvan, and
S Dalac, and
J Sallin, and
D Lambert
December 2021,
Contact dermatitis,
